About the Event
We all know stress is killing us, but physicians do not currently have a precision diagnostic for stress biology. Until now! Inmedix is has developed next-generation heart rate variability (HRV) testing as a proprietary and precise measure of stress biology. It’s like Oura ring, Fitbit, or the Apple Watch, but with FDA hardware, software, and clinical standards on an proprietary SaaS platform. Inmedix Technology highlights:
- 2 recurrent revenue streams (annual lease AND per test using current CPT billing codes)
- Of 231 US rheumatologists independently polled: 96% want the device ASAP, alone representing $20M annual revenue
- 90% SaaS margins
- Proximity to commercialization (12 months)
Join our webinar to hear Inmedix CEO, Andrew J. Holman, MD discuss the company’s upcoming milestones and how their approach to stress testing will transform rheumatology and several other medical specialties.